ImmuPharma expects new Lupozor study to begin in H2 2023
News release
by
ImmuPharma PLC
London, UK
|
February 09, 2023 06:07 AM Eastern Standard Time
ImmuPharma PLC (AIM:IMM, OTC:IMMPF) chief executive Tim McCarthy spoke to Thomas Warner at Proactive's London studio after announcing that its partner Avion Pharmaceuticals is to launch an adaptive phase II/III clinical study on Lupuzor, the former’s discovery and putative treatment for systemic lupus erythematosus (SLE). McCarthy reveals the reasons for choosing the particular type of study and explains what else investors can expect from ImmuPharma during 2023.
Contact Details
Proactive UK Ltd
Proactive UK Ltd
+44 20 7989 0813
